Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study

BACKGROUND: Despite the demonstrated efficacy and safety of biosimilar filgrastim-aafi (Nivestim™), few studies have compared its use in real-life clinical practice to the originator filgrastim (Neupogen™). OBJECTIVES: This study aimed to compare the effectiveness and safety of filgrastim and filgra...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Rabayah, Abeer A., Al Mashni, Ola, Hanoun, Esraa, Al Qasem, Weam, Al Momani, Deema, Al Froukh, Rawan Fawzi, Sawalha, Razan, Hammoudeh, Suzan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712837/
https://www.ncbi.nlm.nih.gov/pubmed/36070082
http://dx.doi.org/10.1007/s40801-022-00312-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712837/
https://www.ncbi.nlm.nih.gov/pubmed/36070082
http://dx.doi.org/10.1007/s40801-022-00312-8

Ejemplares similares